Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

847 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Subcutaneous omacetaxine mepesuccinate in patients with chronic-phase chronic myeloid leukemia previously treated with 2 or more tyrosine kinase inhibitors including imatinib.
Cortes JE, Nicolini FE, Wetzler M, Lipton JH, Akard L, Craig A, Nanda N, Benichou AC, Leonoudakis J, Khoury HJ, Hochhaus A, Baccarani M, Kantarjian HM. Cortes JE, et al. Among authors: nanda n. Clin Lymphoma Myeloma Leuk. 2013 Oct;13(5):584-91. doi: 10.1016/j.clml.2013.03.020. Epub 2013 Jun 17. Clin Lymphoma Myeloma Leuk. 2013. PMID: 23787123 Free PMC article. Clinical Trial.
Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation.
Cortes J, Lipton JH, Rea D, Digumarti R, Chuah C, Nanda N, Benichou AC, Craig AR, Michallet M, Nicolini FE, Kantarjian H; Omacetaxine 202 Study Group. Cortes J, et al. Among authors: nanda n. Blood. 2012 Sep 27;120(13):2573-80. doi: 10.1182/blood-2012-03-415307. Epub 2012 Aug 15. Blood. 2012. PMID: 22896000 Free PMC article. Clinical Trial.
Pharmacokinetic study of omacetaxine mepesuccinate administered subcutaneously to patients with advanced solid and hematologic tumors.
Nemunaitis J, Mita A, Stephenson J, Mita MM, Sarantopoulos J, Padmanabhan-Iyer S, Nanda N, Gleich L, Benichou AC, Craig A. Nemunaitis J, et al. Among authors: nanda n. Cancer Chemother Pharmacol. 2013 Jan;71(1):35-41. doi: 10.1007/s00280-012-1963-2. Epub 2012 Oct 4. Cancer Chemother Pharmacol. 2013. PMID: 23053254 Free PMC article. Clinical Trial.
Critical role for Syk in responses to vascular injury.
Andre P, Morooka T, Sim D, Abe K, Lowell C, Nanda N, Delaney S, Siu G, Yan Y, Hollenbach S, Pandey A, Gao H, Wang Y, Nakajima K, Parikh SA, Shi C, Phillips D, Owen W, Sinha U, Simon DI. Andre P, et al. Among authors: nanda n. Blood. 2011 Nov 3;118(18):5000-10. doi: 10.1182/blood-2011-06-360743. Epub 2011 Aug 31. Blood. 2011. PMID: 21881044 Free PMC article.
Novel targets for antithrombotic drug discovery.
Nanda N, Phillips DR. Nanda N, et al. Blood Cells Mol Dis. 2006 Mar-Apr;36(2):228-31. doi: 10.1016/j.bcmd.2005.12.026. Epub 2006 Feb 13. Blood Cells Mol Dis. 2006. PMID: 16473533 Review.
Recent data using proteomics and genomics strategies have established that signaling pathways during platelet aggregation are triggered by two homophilic adhesion molecules, CD84 and CD150 (SLAM), and by a novel EGF-containing receptor, PEAR1, which are tyrosine-phosphorylated in …
Recent data using proteomics and genomics strategies have established that signaling pathways during platelet aggregation are triggered by t …
An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101.
Doebele RC, Davis LE, Vaishnavi A, Le AT, Estrada-Bernal A, Keysar S, Jimeno A, Varella-Garcia M, Aisner DL, Li Y, Stephens PJ, Morosini D, Tuch BB, Fernandes M, Nanda N, Low JA. Doebele RC, et al. Among authors: nanda n. Cancer Discov. 2015 Oct;5(10):1049-57. doi: 10.1158/2159-8290.CD-15-0443. Epub 2015 Jul 27. Cancer Discov. 2015. PMID: 26216294 Free PMC article. Clinical Trial.
Indian Consensus on the Role and Position of Angiotensin Receptor-neprilysin Inhibitors in the Management of Heart Failure.
Chopra HK, Ponde C, Wander GS, Nair T, Ray S, Khullar D, Nanda NC, Narula J, Kasliwal RR, Rana DS, Kirpalani A, Sawhney JS, Chandra P, Mehta Y, Kumar V, Tiwari S, Pancholia AK, Kher V, Bansal S, Mittal S, Kerkar P, Sahoo PK, Hotchandani R, Prakash S, Chauhan N, Rastogi V, Abdullakutty J, Shanmugasundaram S, Tiwaskar M, Sinha A, Gupta V, Mishra SS, Routray SN, Omar AK, Swami OC, Jaswal A, Alam S, Passey R, Rajput R, Paul J, Kapoor A, Dorairaj P, Chandra S, Malhotra P, Singh VP, Bansal M, Jain S, Shah P, Bhargava M, Vijayalakshmi IB, Varghaese K, Jain D, Goel A, Mahmood K, Gaur N, Tandon R, Moorthy A, George S, Katyal VK, Mantri RR, Mehrotra R, Bhalla D, Mittal V, Rao S, Jagia M, Singh H, Awasthi S, Sattur A, Mishra R, Pandey A, Chawla R, Jaggi S, Sehgal B, Sehgal A, Goel N, Gupta R, Kubba S, Chhabra A, Bagga S, Shastry RN. Chopra HK, et al. Among authors: nanda nc. J Assoc Physicians India. 2024 Sep;72(9):75-82. doi: 10.59556/japi.72.0664. J Assoc Physicians India. 2024. PMID: 39291524
847 results